Catalio Capital Management, LP, a NYC-based multi-strategy life sciences investment firm, closed its third venture fund, Catalio Nexus Fund III, at more than $381m.
The fund received backing from current investors and a number of new, global institutional investors, foundations and endowments.
Fund III will invest in breakthrough biomedical technology companies at all stages of growth, from inception to IPO. Many of the companies in which the Fund invests are founded by Catalio Venture Partners, a group of 36 serial scientist-entrepreneurs at top-tier academic institutions in the U.S. and Europe, each with a track record of starting up and spinning out businesses.
Launched in 2020 and led by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio manages more than $1 billion in assets across its private equity, private credit, and public equities strategies.
Fund III is Catalio’s largest closed-end fund to date. Previously, the firm raised $15 million for Nexus Fund I and $100 million for Nexus Fund II.
Five Catalio portfolio companies went public over the last year, including Recursion Pharmaceuticals (NASDAQ: RXRX), Compass Pathways (NASDAQ: CMPS) and ATAI Life Sciences (NASDAQ: ATAI). Portfolio company Thrive Earlier Detection, founded by Catalio Venture Partner Dr. Bert Vogelstein at Johns Hopkins, was acquired by EXACT Sciences (NASDAQ: EXAS) for $2.15 billion in January 2021; while Personal Genome Diagnostics was acquired by LabCorp (NYSE: LH) for $500 million in February 2022. The firm has also backed Octant, Pheast Therapeutics, Affini-T’s.
Catalio has offices in New York, Baltimore, and London.